First trimester maternal serum placental protein 13 for the prediction of pre‐eclampsia in women with a priori high risk

To evaluate whether first trimester maternal serum PP13 can predict pre‐eclampsia among women with a priori high risk.

[1]  T. Khong,et al.  Inadequate maternal vascular response to placentation in pregnancies complicated by pre‐eclampsia and by small‐for‐gestational age infants , 1986 .

[2]  K. Nicolaides,et al.  Maternal serum soluble adhesion molecule levels at 11+0–13+6 weeks and subsequent development of pre-eclampsia , 2007, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[3]  W. B. Robertson,et al.  Abnormal placentation , 2019, Analgesia, Anaesthesia and Pregnancy.

[4]  L. Stewart,et al.  Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data , 2007, The Lancet.

[5]  R. Carpenter,et al.  Transvaginal Doppler ultrasound of the uteroplacental circulation in the early prediction of pre-eclampsia and intrauterine growth retardation. , 1996, British journal of obstetrics and gynaecology.

[6]  K. Spencer,et al.  First‐trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes , 2008, Prenatal diagnosis.

[7]  Hans Bohn,et al.  Functional analyses of placental protein 13/galectin-13. , 2004, European journal of biochemistry.

[8]  K. Nicolaides,et al.  Prediction of pregnancy complications by first‐trimester maternal serum PAPP‐A and free β‐hCG and with second‐trimester uterine artery Doppler , 2005, Prenatal diagnosis.

[9]  A. Seidler,et al.  Antiplatelet agents for preventing pre-eclampsia and its complications. , 2007, The Cochrane database of systematic reviews.

[10]  R. Romero,et al.  Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. , 2007, American journal of obstetrics and gynecology.

[11]  S. Cicero,et al.  Screening for pre‐eclampsia and fetal growth restriction by uterine artery Doppler at 11–14 weeks of gestation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[12]  L. Shulman.  First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction , 2008 .

[13]  B. Sibai,et al.  What we have learned about preeclampsia. , 2003, Seminars in perinatology.

[14]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[15]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[16]  A. Admon,et al.  Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. , 2004, Placenta.

[17]  Jm Roberts,et al.  Pathogenesis and genetics of pre-eclampsia , 2001, The Lancet.

[18]  H. Meiri,et al.  Placental Protein 13 as an Early Marker for Preeclampsia: A Prospective Longitudinal Study , 2009 .

[19]  K. Spencer,et al.  Second‐trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre‐eclampsia , 2007, Prenatal diagnosis.

[20]  S. Campbell,et al.  A prospective management study of slow‐release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[21]  I. Kovalszky,et al.  Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome , 2008, Virchows Archiv.

[22]  R. T. Lie,et al.  Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. , 2001, BMJ : British Medical Journal.

[23]  Jean-Marie Moutquin,et al.  The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) , 2001, Hypertension in pregnancy.

[24]  H. Meiri,et al.  Placental protein 13 as an early marker for pre‐eclampsia: a prospective longitudinal study * , 2008, BJOG : an international journal of obstetrics and gynaecology.

[25]  H. Gee,et al.  Aspirin for the Prevention of Preeclampsia in Women With Abnormal Uterine Artery Doppler: A Meta‐Analysis , 2001, Obstetrics and gynecology.

[26]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[27]  A. Weindling,et al.  The confidential enquiry into maternal and child health (CEMACH) , 2003, Archives of disease in childhood.

[28]  K. Nicolaides,et al.  A novel approach to first‐trimester screening for early pre‐eclampsia combining serum PP‐13 and Doppler ultrasound , 2005, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[29]  G. Dekker,et al.  Pre-eclampsia , 2005, The Lancet.

[30]  G. Burton,et al.  In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. , 2001, The American journal of pathology.

[31]  H. Cuckle,et al.  First-trimester maternal serum PP13 in the risk assessment for preeclampsia. , 2008, American journal of obstetrics and gynecology.

[32]  A. Hingorani,et al.  Preeclampsia and Risk of Cardiovascular Disease and Cancer in Later Life: Systematic Review and Meta-analysis , 2008 .

[33]  K. Spencer,et al.  First‐trimester maternal serum PP‐13, PAPP‐A and second‐trimester uterine artery Doppler pulsatility index as markers of pre‐eclampsia , 2007, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[34]  Robert N. Taylor,et al.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.

[35]  N. Wald,et al.  Tests using single markers , 2000 .

[36]  K. Nicolaides,et al.  Low levels of maternal serum PAPP‐A in the first trimester and the risk of pre‐eclampsia , 2008, Prenatal diagnosis.

[37]  B. Huppertz,et al.  Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia , 2008, Fetal Diagnosis and Therapy.

[38]  R. Gonenc,et al.  Placental Protein 13 ( PP-13 ) : Effects on Cultured Trophoblasts , and Its Detection in Human Body Fluids in Normal and Pathological Pregnancies , 2004 .

[39]  R. Pijnenborg,et al.  A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre‐eclamptic pregnancies , 1994, British journal of obstetrics and gynaecology.

[40]  L. Magee,et al.  Subclassification of Preeclampsia , 2003, Hypertension in pregnancy.

[41]  Z. Berente,et al.  Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein. , 1999, Placenta.

[42]  Wenjiang J. Fu,et al.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[43]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.